Abbott Laboratories (NYSE:ABT) Price Target Raised to $119.00

Key Points

• Wells Fargo raised Abbott’s price target to $119 from $112 and maintained an “overweight” rating, implying 17.22% upside. Analysts overall rate the stock “Moderate Buy,” with an average target of $118.12.
• Abbott reported quarterly earnings of $1.42 per share and revenue of $13.01 billion, with revenue up 14.5% year over year. However, the company lowered its 2026 sales-growth outlook because of diabetes-related pricing pressure and weakness in some medical-device businesses.
• Institutional investors own 75.18% of Abbott’s shares, while the company plans to separate its roughly $8.5 billion Nutrition business into a publicly traded company by the end of 2027.

Abbott Laboratories (NYSE:ABT - Get Free Report) had its target price lifted by equities research analysts at Wells Fargo & Company from $112.00 to $119.00 in a research report issued on Thursday, Benzinga reports. The firm presently has an "overweight" rating on the healthcare product maker's stock. Wells Fargo & Company's price target indicates a potential upside of 17.22% from the stock's previous close.

Several other equities analysts have also recently weighed in on ABT. JPMorgan Chase & Co. dropped their price target on shares of Abbott Laboratories from $120.00 to $118.00 and set an "overweight" rating on the stock in a research report on Thursday. TD Cowen decreased their price objective on Abbott Laboratories from $135.00 to $118.00 and set a "buy" rating for the company in a report on Thursday. BTIG Research lowered their price objective on Abbott Laboratories from $134.00 to $125.00 and set a "buy" rating for the company in a research note on Thursday. Weiss Ratings upgraded Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, September 18th. Finally, Citigroup lifted their target price on Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a research report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $118.12.

Abbott Laboratories Stock Up 1.0%

ABT stock traded up $1.01 during midday trading on Thursday, reaching $101.52. 2,579,517 shares of the company's stock traded hands, compared to its average volume of 11,288,301. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The firm's fifty day moving average price is $105.47 and its 200-day moving average price is $98.28. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $132.02. The company has a market cap of $175.66 billion, a price-to-earnings ratio of 32.76, a P/E/G ratio of 1.90 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, meeting analysts' consensus estimates of $1.42. The firm had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business's quarterly revenue was up 14.5% compared to the same quarter last year. During the same period last year, the firm earned $1.30 earnings per share. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Abbott Laboratories

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Abbott Laboratories by 4.6% during the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock valued at $13,843,610,000 after acquiring an additional 6,769,518 shares during the last quarter. State Street Corp lifted its holdings in Abbott Laboratories by 1.7% during the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker's stock worth $7,343,246,000 after acquiring an additional 1,350,766 shares during the period. Bank of America Corp DE purchased a new position in Abbott Laboratories in the second quarter worth $1,603,607,000. Deutsche Bank AG boosted its position in Abbott Laboratories by 18.6% in the second quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker's stock worth $1,515,963,000 after purchasing an additional 2,614,965 shares during the last quarter. Finally, Legal & General Group Plc purchased a new position in Abbott Laboratories in the second quarter worth $1,082,524,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Third-quarter performance was broadly solid: adjusted earnings were $1.42 per share, in line with consensus, while revenue rose 14.5% year over year to $13.01 billion, slightly exceeding estimates. Comparable sales increased 7%. Abbott reaffirmed its full-year adjusted EPS guidance. Abbott third-quarter results
• Positive Sentiment: Analysts remain constructive despite trimming some targets. Robert W. Baird raised its target to $123, while BTIG, JPMorgan and TD Cowen maintained buy-equivalent ratings with targets ranging from $118 to $125, implying meaningful upside from recent levels.
• Positive Sentiment: Abbott received European regulatory clearance for Cologuard Plus, expanding the potential market for its noninvasive colorectal-cancer screening test. Cologuard Plus European approval
• Neutral Sentiment: Abbott plans to separate its approximately $8.5 billion Nutrition business—including Ensure, Similac, Pedialyte, PediaSure and Glucerna—into an independent, publicly traded company through a tax-free distribution to shareholders by the end of 2027. Management expects the transaction to give both companies more focused growth strategies, though investors must assess execution and the future value of the separated businesses. Abbott Nutrition spinoff announcement
• Negative Sentiment: Abbott lowered its 2026 sales-growth outlook, citing diabetes-related pricing pressure and weakness in electrophysiology and other medical-device areas. That guidance reduction overshadowed the quarterly revenue performance and caused the stock to decrease after the announcement. Reuters Abbott outlook report
• Negative Sentiment: Although adjusted EPS matched the broader consensus, some services reported a modest miss against the higher Zacks estimate of $1.43. Combined with the lower sales outlook and uncertainty around the spinoff, this has increased near-term investor caution.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.